Form 8-K - Current report:
SEC Accession No. 0000950170-24-132818
Filing Date
2024-12-03
Accepted
2024-12-03 16:45:06
Documents
12
Period of Report
2024-12-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K kzr-20241203.htm   iXBRL 8-K 49525
2 EX-4.1 kzr-ex4_1.htm EX-4.1 30994
  Complete submission text file 0000950170-24-132818.txt   231782

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kzr-20241203.xsd EX-101.SCH 46825
14 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20241203_htm.xml XML 6134
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 241523399
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)